Cardinal Health (CAH) Dividend Stock Profile

Company Overview

Cardinal Health, Inc. (NYSE: CAH) is a cornerstone of the American healthcare system. As one of the "Big Three" wholesale pharmaceutical distributors, alongside McKesson and AmerisourceBergen, Cardinal Health plays an indispensable role in the U.S. healthcare supply chain. Headquartered in Dublin, Ohio, the company, which went public in 1983, serves as a critical intermediary between pharmaceutical manufacturers and healthcare providers.

Its operations are vast, encompassing the distribution of pharmaceuticals, medical-surgical products, and laboratory supplies to a wide range of customers, including retail pharmacies, hospitals, ambulatory surgery centers, and clinical laboratories. Essentially, if a healthcare product is used in a U.S. hospital or sold in a pharmacy, there's a strong probability that Cardinal Health was involved in getting it there.

The Business Model: Two Core Segments

Cardinal Health operates through two primary segments:

1. Pharmaceutical Segment: This is the larger of the two segments by revenue. It distributes a vast portfolio of branded and generic pharmaceutical, specialty pharmaceutical, and over-the-counter healthcare products. Its customers include major retail pharmacy chains, independent pharmacies, and institutional providers like hospitals and health systems.

2. Medical Segment: This segment focuses on the distribution of a broad range of medical, surgical, and laboratory products. It also manufactures its own line of Cardinal Health branded medical products, such as surgical gloves, gowns, and fluid management products. This segment serves hospitals, surgery centers, and other healthcare facilities, providing them with the essential tools needed for patient care.

The sheer scale and logistical complexity of this business create a significant competitive moat. The industry is an oligopoly, making it extremely difficult for new entrants to compete effectively.

Dividend History & Track Record

For dividend investors, a company's history of shareholder returns is a primary area of focus, and Cardinal Health has a long and distinguished record.

The Mark of a Dividend Aristocrat

Cardinal Health is a member of the prestigious S&P 500 Dividend Aristocrats index. To earn this title, a company must have increased its dividend for at least 25 consecutive years. Cardinal Health has far surpassed this benchmark, boasting a track record of over 35 consecutive years of dividend increases. This places it in an elite group of companies that have demonstrated an unwavering commitment to returning capital to shareholders through various economic cycles, market crashes, and industry shifts.

This long history of consistent dividend growth provides a strong signal of financial stability and a management team that prioritizes shareholder returns. For investors seeking reliable and predictable income streams, this Aristocrat status is a significant mark of quality.

Key Financial Metrics for Dividend Investors

Beyond its history, a thorough analysis of CAH's current financial health is crucial for determining the safety and future growth potential of its dividend.

Dividend Yield

As of late 2024, Cardinal Health's forward annual dividend stands at approximately $2.02 per share. With the stock trading around $103, this translates to a dividend yield of roughly 1.96%. While not a high-yield stock, this is often competitive with or slightly above the average yield of the S&P 500. The yield provides a solid income stream while investors wait for potential capital appreciation.

Payout Ratio: A Measure of Safety

Perhaps the most critical metric for dividend safety is the payout ratio, which measures the proportion of earnings paid out as dividends. A lower ratio indicates a greater cushion to maintain and grow the dividend, even if earnings decline temporarily.

• Earnings-Based Payout Ratio: Based on the midpoint of its fiscal year 2024 adjusted earnings per share (EPS) guidance of around $7.35, the forward dividend of ~$2.02 represents a payout ratio of just 27.5%. This is an exceptionally low and healthy ratio, suggesting the dividend is extremely well-covered by earnings.

• Cash Flow-Based Payout Ratio: Many analysts prefer to use free cash flow (FCF), as it represents the actual cash available to run the business and pay dividends. Cardinal Health consistently generates strong FCF, and its dividend payments consume only a small fraction of it. This low cash payout ratio further reinforces the dividend's safety.

This conservative payout ratio gives the company significant flexibility to reinvest in the business, manage its debt, and continue increasing its dividend for years to come.

Earnings and Cash Flow Growth

Sustainable dividend growth is impossible without corresponding growth in earnings and cash flow. After a period of stagnation, largely due to challenges from opioid litigation and other pressures, Cardinal Health's earnings have shown renewed strength. The company's guidance for significant EPS growth in fiscal 2024 is a positive sign that its strategic initiatives are bearing fruit. Continued growth in its core segments, particularly in higher-margin specialty pharma and medical products, will be key to funding future dividend hikes.

Balance Sheet Health

Cardinal Health has been actively working to strengthen its balance sheet. A primary use of its cash flow in recent years has been to pay down debt incurred from acquisitions and to cover legal settlements. The company maintains an investment-grade credit rating, but investors should continue to monitor its debt-to-EBITDA ratio and overall leverage. A healthy balance sheet is essential for navigating economic downturns and ensuring the dividend is not compromised by high interest payments.

Dividend Growth Analysis

While Cardinal Health's dividend is undeniably safe, its growth rate has been a point of concern for many dividend growth investors.

A Tale of Two Growth Periods

Historically, CAH was a robust dividend grower. However, over the past 5-7 years, the dividend growth rate has slowed to a crawl. The most recent increase was a mere 1%. This trend is clear when looking at the dividend's compound annual growth rate (CAGR):

• 1-Year Growth Rate: ~1.0%
• 3-Year CAGR: ~1.0%
• 5-Year CAGR: ~1.3%
• 10-Year CAGR: ~5.0%

The 10-year figure is skewed by much larger increases in the earlier part of the decade. The recent trend shows a clear policy of minimal, token increases designed solely to maintain its Dividend Aristocrat status. This slowdown is largely attributed to management prioritizing cash flow for debt reduction and settling the massive opioid-related lawsuits.

For investors, this is a critical consideration. While the starting yield is decent and the dividend is safe, the low growth rate will not lead to rapid compounding of income. Tools like DripEdge can be invaluable for investors to track these slowing growth trends and simulate how such low growth impacts their long-term passive income projections compared to faster-growing dividend stocks.

The key question for the future is whether management will re-accelerate dividend growth once the balance sheet is in its target range and the bulk of litigation costs are in the past.

Risks & Considerations

No investment is without risk, and Cardinal Health faces several industry-specific and company-specific challenges.

The Shadow of Opioid Litigation

As a primary distributor, Cardinal Health was a central figure in nationwide litigation concerning its role in the opioid crisis. The company has agreed to pay billions of dollars as part of a comprehensive settlement. While this has removed a major source of uncertainty, the financial impact has been significant, diverting cash flow that could have been used for larger dividend increases or other investments.

Margin Pressure and Competition

The pharmaceutical distribution industry is intensely competitive and operates on notoriously thin profit margins. Cardinal Health is in constant negotiation with large, powerful customers (like CVS Health, a major client) and suppliers. Any pressure on these margins, whether from competition, customer consolidation, or changes in drug pricing, can have a material impact on profitability.

Regulatory and Political Headwinds

The entire healthcare sector is subject to significant regulatory oversight and political scrutiny. Potential changes in U.S. healthcare policy, particularly those aimed at controlling drug prices (e.g., through government negotiation), could negatively affect the profitability of distributors. This remains a persistent, albeit unpredictable, risk.

Is CAH a Good Dividend Stock?

Whether Cardinal Health is a suitable investment depends heavily on the investor's individual goals and risk tolerance.

The Verdict for Different Investor Profiles

• For the Conservative Income Investor: For an investor whose primary goal is a safe, reliable, and predictable stream of income, CAH is a compelling choice. Its Dividend Aristocrat status, essential business model, and very low payout ratio make the current dividend exceptionally secure. It's a classic 'sleep well at night' stock for income.

• For the Dividend Growth Investor: An investor seeking high single-digit or double-digit annual dividend growth will likely be disappointed. The current 1% growth rate significantly lags inflation and will not compound income quickly. This type of investor may find better opportunities elsewhere, at least until CAH's management signals a shift in its capital allocation policy towards more aggressive dividend growth.

• For the Total Return Investor: From a total return perspective, the thesis is more balanced. The stock has performed well recently as earnings have recovered and litigation uncertainty has faded. An investment in CAH today is a bet on continued operational improvement, share price appreciation, and a modest but extremely safe dividend. The combination could still lead to attractive total returns.

In conclusion, Cardinal Health is a high-quality company with a safe dividend. However, it is currently a 'dividend safety' stock, not a 'dividend growth' stock. Investors must weigh the security of the payout against its near-stagnant growth rate.

FAQ

Disclaimer: The information provided is for educational and informational purposes only and does not constitute financial, investment, or legal advice. DripEdge is not a registered investment advisor. Past performance does not guarantee future results. Always do your own research or consult a qualified financial professional before making investment decisions.